State Street SPDR S&P Pharmaceuticals ETF
XPH
77 hedge funds and large institutions have $261M invested in State Street SPDR S&P Pharmaceuticals ETF in 2015 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 29 reducing their positions, and 17 closing their positions.
17% more call options, than puts
Call options by funds: $924K | Put options by funds: $788K
0% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 29
9% less funds holding
Funds holding: 85 → 77 (-8)
22% less capital invested
Capital invested by funds: $335M → $261M (-$73.4M)
30.04% less ownership
Funds ownership: 61.65% → 31.61% (-30%)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$16M |
| 3 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$12.9M |
| 4 |
Citigroup
New York
|
+$9.15M |
| 5 |
Goldman Sachs
New York
|
+$8.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$19.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$16M |
| 3 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
-$7.75M |
| 4 |
VC
Vicus Capital
State College,
Pennsylvania
|
-$6.47M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$5.89M |
XPH Hedge Fund Activity: Q3 2015 in Review
77 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2015, worth a combined $261M — down 22% from $335M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of XPH and 10 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 29 added.
The largest buyer was Susquehanna International Group, adding an estimated $20.4M. The largest seller was Morgan Stanley, cutting an estimated $19.2M.
- 77 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2015, down from 85 in Q2 2015.
- Funds reported $261M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2015, down 22% quarter-over-quarter.
- 10 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2015 and 17 closed out, a net change of -7 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2015 was Susquehanna International Group, an estimated $20.4M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2015 was Morgan Stanley, an estimated $19.2M sold.
Based on aggregated 13F filings for Q3 2015.